Advanced therapy medicinal products (ATMPs) typically come with high price tags compared to more traditional medicinal treatments. While health technology assessment (HTA) agencies are willing to exercise flexibility in their value assessments when it comes to ATMPs, this is because of the target patient population, not the technology itself.
Advanced Therapies For Common Conditions In England Won’t Get Extra Funding, Says Ex-NICE Official
Health technology assessment agencies are willing to pay more than usual for advanced therapies that treat rare or severe diseases, but an advanced therapy for a common condition would not qualify for such a modifier, a former senior figure at England’s NICE says.
